Основная статистика
| LEI | 549300YVIWV7HJ5WHI66 |
| CIK | 1797768 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kinnate Biopharma Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| November 13, 2024 |
KNTE / Kinnate Biopharma Inc. / Vida Ventures, LLC - SC 13G/A Passive Investment SC 13G/A 1 d809400dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* KINNATE BIOPHARMA INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Ch |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-39743 Commission File Number KINNATE BIOPHARMA INC. (Exact name of registrant as specified in i |
|
| April 5, 2024 |
KNTE / Kinnate Biopharma Inc. / Foresite Capital Fund V, L.P. - AMENDMENT NO. 6 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49705R105 (CUSIP Number) Dennis Ryan Foresite Capital Management, LLC 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939 (415) 877-4887 (Name, Address and Telepho |
|
| April 3, 2024 |
SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION KINNATE BIOPHARMA INC. * * * * * * * * EX-3.1 Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. * * * * * * * * I. The name of this corporation is Kinnate Biopharma Inc. II. The registered office of the corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle 19801, and the name of the registered agent of the corpor |
|
| April 3, 2024 |
AMENDED AND RESTATED BYLAWS KINNATE BIOPHARMA INC. (A DELAWARE CORPORATION) EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF KINNATE BIOPHARMA INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle 19801, or in such other location as the Board of Directors may from time to time deter |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 3) Kinnate Biopharma Inc. (Name of Subject Company) Kinnate Biopharma Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSI |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 3, 2024 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 3, 2024 |
EX-99.(a)(5)(D) Exhibit (a)(5)(D) XOMA Corporation Announces Closing of Tender Offer Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right EMERYVILLE, Calif., April 3, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of impr |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| April 3, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value |
|
| April 3, 2024 |
As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39743 KINNATE BIOPHA |
|
| March 28, 2024 |
KINNATE BIOPHARMA INC. COMPENSATION RECOVERY POLICY As adopted on July 25, 2023 Exhibit 97.1 KINNATE BIOPHARMA INC. COMPENSATION RECOVERY POLICY As adopted on July 25, 2023 Kinnate Biopharma Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this Compensation Recovery Policy (this “Policy”). This Policy is intended to further the Company’s pay-for-performance philosophy and t |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) Kinnate Biopharma Inc. (Name of Subject Company) Kinnate Biopharma Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSI |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value $0.0001 Pe |
|
| March 19, 2024 |
Table of Contents Exhibit (a)(1)(A) Amended and Restated Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC. |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) Kinnate Biopharma Inc. (Name of Subject Company) Kinnate Biopharma Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSI |
|
| March 19, 2024 |
Exhibit (a)(5)(C) XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. |
|
| March 4, 2024 |
Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of KINNATE BIOPHARMA INC. |
|
| March 4, 2024 |
(remainder of page intentionally left blank) Exhibit (e)(17) 103 Montgomery Street, Suite 150 The Presidio of San Francisco San Francisco, CA 94129 O: 858. |
|
| March 4, 2024 |
MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT Exhibit (d)(2) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT This Mutual Confidential Disclosure Agreement (this “Agreement”), effective as of November 11, 2023 (the “Effective Date”), is entered into by and between Kinnate Biopharma Inc. |
|
| March 4, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) Kinnate Biopharma Inc. (Name of Subject Company) Kinnate Biopharma Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities |
|
| March 4, 2024 |
(remainder of page intentionally left blank) Exhibit (e)(19) 103 Montgomery Street, Suite 150 The Presidio of San Francisco San Francisco, CA 94129 O: 858. |
|
| March 4, 2024 |
(remainder of page intentionally left blank) Exhibit (e)(18) 103 Montgomery Street, Suite 150 The Presidio of San Francisco San Francisco, CA 94129 O: 858. |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value $0.0001 Per Share (Title of |
|
| March 4, 2024 |
Exhibit 107 Calculation of Filing Fee Tables SC TO-T (Form Type) KINNATE BIOPHARMA INC. |
|
| March 4, 2024 |
Table of Contents Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC. |
|
| March 4, 2024 |
Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC. |
|
| March 4, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of KINNATE BIOPHARMA INC. |
|
| March 4, 2024 |
Exhibit (e)(16) 103 Montgomery Street, Suite 150 The Presidio of San Francisco San Francisco, CA 94129 O: 858. |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) Kinnate Biopharma Inc. (Name of Subject Company) Kinnate Biopharma Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSI |
|
| March 1, 2024 |
Press release dated March 1, 2024 Exhibit 99.1 Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. • The transaction is in furtherance of Kinnate’s previously announced pursuit of strategic alternatives. • This ac |
|
| March 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2024 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| March 1, 2024 |
Exhibit 99.1 Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories • Kinnate has entered into an Asset Purchase Agreement (the “APA”) with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets. • The transaction is in furtherance of Kinnate’s previously announced pursuit of strategic alternatives. • This ac |
|
| March 1, 2024 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT Dated February 27, 2024 by and among KINNATE BIOPHARMA INC. AND PIERRE FABRE MÉDICAMENT, SAS ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”), effective as of February 27, 2024 (the “Effective Date”), is made and entered into by and among Kinnate BioPharma Inc., a Delaware corporation (“Seller”) and Pierre Fabre Médicament, SAS, a corpo |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO (Rule 14d-100) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 KINNATE BIOPHARMA INC. (Name of Subject Company (Issuer)) XRA 1 CORP. (Name of Filing Persons (Offeror 1)) XOMA CORPORATION (Name of Filing Persons (Parent of Offeror)) Common Stock, Par Value $0.0001 Per |
|
| February 27, 2024 |
Exhibit 99.1 XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio EMERYVILLE, Calif., February 16, 2024 (GLOBE NEWSWIRE) – XOMA Corporation (NASDA |
|
| February 22, 2024 |
EX-99.1 2 eh240450910ex01.htm EXHIBIT 1 EXHIBIT 1 Confidential SUPPORT AGREEMENT This SUPPORT AGREEMENT (“Agreement”), dated as of February 16, 2024, is made by and among XOMA Corporation, a Delaware corporation (“Parent”), XRA 1 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the undersigned holder (“Stockholder”) of shares of common stock, par value $0.0 |
|
| February 22, 2024 |
KNTE / Kinnate Biopharma Inc. / Foresite Capital Fund V, L.P. - AMENDMENT NO. 5 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49705R105 (CUSIP Number) Dennis Ryan Foresite Capital Management, LLC 900 Larkspur Landing Circle, Suite 150, Larkspur, CA 94939 (415) 877-4887 (Name, Address and Telepho |
|
| February 22, 2024 |
EX-99.2 3 eh240450910ex02.htm EXHIBIT 2 EXHIBIT 2 Confidential SUPPORT AGREEMENT This SUPPORT AGREEMENT (“Agreement”), dated as of February 16, 2024, is made by and among XOMA Corporation, a Delaware corporation (“Parent”), XRA 1 Corp., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the undersigned holder (“Stockholder”) of shares of common stock, par value $0.0 |
|
| February 21, 2024 |
EX-99.1 2 ss3056108ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 6 to the Statement on Schedule 13D, dated February 16, 2024, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as |
|
| February 21, 2024 |
KNTE / Kinnate Biopharma Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Kinnate Biopharma Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 49705R105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC OrbiMed Capital GP VIII LLC OrbiMed Asia GP IV, L.P. O |
|
| February 21, 2024 |
Exhibit 99.1 Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share SAN FRANCISCO and SAN DIEGO – February 16, 2024 – Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive me |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. ) Kinnate Biopharma Inc. (Name of Subject Company) Kinnate Biopharma Inc. (Name of Persons Filing Statement) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSIP |
|
| February 16, 2024 |
Exhibit 99.1 Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share SAN FRANCISCO and SAN DIEGO – February 16, 2024 – Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or the “Company”), a clinical-stage precision oncology company, today announced it has entered into a definitive me |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date earliest event reported): February 16, 2024 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission F |
|
| February 16, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER DATED AS OF FEBRUARY 16, 2024 AMONG XOMA CORPORATION XRA 1 CORP. AND KINNATE BIOPHARMA INC. Table of Contents Page Article I DEFINITIONS 2 Section 1.01 Definitions 2 Section 1.02 Interpretation and Rules of Construction 13 Article II THE OFFER 14 Section 2.01 The Offer 14 Section 2.02 Company Actions 18 Article III THE MERGER 19 Section 3.01 The Merger 19 S |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| February 14, 2024 |
KNTE / Kinnate Biopharma Inc. / Nextech V Oncology S.C.S., SICAV-SIF - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock $0.0001 par value (Title of Class of Securities) 49705R 10 5 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2024 |
KNTE / Kinnate Biopharma Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2024 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission F |
|
| November 27, 2023 |
KNTE / Kinnate Biopharma Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 27, 2023 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Kinnate Biopharma Inc. and further agree to the filing of |
|
| November 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 16, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| November 17, 2023 |
EX-99.2 3 ss2725393ex9902.htm JOINT FILING AGREEMENT Exhibit 2 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 5 to the Statement on Schedule 13D, dated November 17, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, |
|
| November 17, 2023 |
EX-99.1 2 eh230422217ex01.htm EXHIBIT 1 EXHIBIT 1 Foresite Capital Fund IV, L.P. Foresite Capital Fund V, L.P. Foresite Capital Opportunity Fund V, L.P. 900 Larkspur Landing Circle, Suite 150 Larkspur, CA 94939 OrbiMed Private Investments VII, LP OrbiMed Private Investments VIII, LP OrbiMed Asia Partners IV, L.P. OrbiMed Genesis Master Fund, L.P. OrbiMed Partners Master Fund Limited 601 Lexington |
|
| November 17, 2023 |
KNTE / Kinnate Biopharma Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment SC 13D/A 1 ss2725393sc13da.htm AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Kinnate Biopharma Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 49705R105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC OrbiMed |
|
| November 17, 2023 |
KNTE / Kinnate Biopharma Inc / Foresite Capital Fund V, L.P. - AMENDMENT NO. 4 Activist Investment SC 13D/A 1 eh23042221713da4-knte.htm AMENDMENT NO. 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49705R105 (CUSIP Number) Dennis Ryan Foresite Capital Management, LLC 900 Larkspur Landing Circle, Suite 150, Larkspu |
|
| November 17, 2023 |
EX-99.1 2 ss2725393ex9901.htm LETTER Foresite Capital Fund IV, L.P. Foresite Capital Fund V, L.P. Foresite Capital Opportunity Fund V, L.P. 900 Larkspur Landing Circle, Suite 150 Larkspur, CA 94939 OrbiMed Private Investments VII, LP OrbiMed Private Investments VIII, LP OrbiMed Asia Partners IV, L.P. OrbiMed Genesis Master Fund, L.P. OrbiMed Partners Master Fund Limited 601 Lexington Avenue, 54th |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| November 14, 2023 |
EX-99.1 2 eh230420932ex01.htm EXHIBIT 1 EXHIBIT 1 Foresite Capital Fund IV, L.P. Foresite Capital Fund V, L.P. Foresite Capital Opportunity Fund V, L.P. 900 Larkspur Landing Circle, Suite 150 Larkspur, CA 94939 OrbiMed Private Investments VII, LP OrbiMed Private Investments VIII, LP OrbiMed Asia Partners IV, L.P. OrbiMed Genesis Master Fund, L.P. OrbiMed Partners Master Fund Limited 601 Lexington |
|
| November 14, 2023 |
KNTE / Kinnate Biopharma Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Kinnate Biopharma Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 49705R105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC OrbiMed Capital GP VIII LLC OrbiMed Asia GP IV, L.P. O |
|
| November 14, 2023 |
EX-99.1 2 ss2708650ex9901.htm LETTER Foresite Capital Fund IV, L.P. Foresite Capital Fund V, L.P. Foresite Capital Opportunity Fund V, L.P. 900 Larkspur Landing Circle, Suite 150 Larkspur, CA 94939 OrbiMed Private Investments VII, LP OrbiMed Private Investments VIII, LP OrbiMed Asia Partners IV, L.P. OrbiMed Genesis Master Fund, L.P. OrbiMed Partners Master Fund Limited 601 Lexington Avenue, 54th |
|
| November 14, 2023 |
KNTE / Kinnate Biopharma Inc / Foresite Capital Fund V, L.P. - AMENDMENT NO. 3 Activist Investment SC 13D/A 1 eh23042093213da3-knte.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49705R105 (CUSIP Number) Dennis Ryan Foresite Capital Management, LLC 900 Larkspur Landing Circle, Suite 150, Larkspu |
|
| November 14, 2023 |
EX-99.2 3 ss2708650ex9902.htm JOINT FILING AGREEMENT Exhibit 2 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 4 to the Statement on Schedule 13D, dated November 13, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNA |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2023 |
Exhibit 99.1 Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates • Reported promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development • Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 sel |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 15, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commissio |
|
| September 18, 2023 |
Exhibit 99.1 Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring • Promising exarafenib combination data in NRAS mutant melanoma; intend to select two doses in the fourth quarter of 2023 for further development • Plan to file KIN-8741 c-MET inhibitor Investigational New Drug application and nominate a drug candidate for brain-penetrant CDK4 sel |
|
| August 14, 2023 |
KNTE / Kinnate Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 49705R105 (CUSIP Number) August 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| August 8, 2023 |
Exhibit 99.1 Kinnate Biopharma Inc. Reports Second Quarter 2023 Financial Results and Recent Corporate Updates • Received FDA clearance of IND application for brain-penetrant MEK inhibitor, KIN-7136; expect to enter the clinic with Phase 1 trial in the second half of 2023 • Cash, cash equivalents and investments of $204.3 million as of June 30, 2023 anticipated to fund operations into early 2025 S |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNATE BI |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 28, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF KINNATE BIOPHARMA INC. (initially adopted on January 4, 2018) (as amended and restated on November 5, 2020 and July 25, 2023) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCED |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
Exhibit 99.1 Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates • Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting • Provided update on ongoing exarafenib monotherapy dose expansion; data-informed strategy prioritizes enrollment in BRAF Class II-driven solid tumors |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNATE B |
|
| May 10, 2023 |
KNTE / Kinnate Biopharma Inc / Foresite Capital Fund IV, L.P. - SC 13D/A Activist Investment CUSIP NO. 49705R105 13D Page 1 of 16 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49705R105 (CUSIP Number) Dennis Ryan Foresite |
|
| May 8, 2023 |
KNTE / Kinnate Biopharma Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Kinnate Biopharma Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 49705R105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC OrbiMed Capital GP VIII LLC OrbiMed Asia GP IV, L.P. O |
|
| May 8, 2023 |
EX-99.1 2 ss2051727ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 3 to the Statement on Schedule 13D, dated May 4, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as am |
|
| May 3, 2023 |
EX-99.1 2 ss2033598ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No. 2 to the Statement on Schedule 13D, dated April 28, 2023, with respect to the common stock of Kinnate Biopharma Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as |
|
| May 3, 2023 |
KNTE / Kinnate Biopharma Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Kinnate Biopharma Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 49705R105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC OrbiMed Capital GP VIII LLC OrbiMed Asia GP IV, L.P. O |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 17, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 17, 2023 |
Exhibit 99.2 Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance • KIN-7136, a next generation brain-penetrant MEK inhibitor for MAPK-driven advanced adult solid tumors, is expected to enter the clinic in the second half of 2023 • KIN-8741, a highly selective c-MET inhibitor designed to cover acquired resistance in non-sma |
|
| April 17, 2023 |
Exhibit 99.1 First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma • Exarafenib was well-tolerated at substantial monotherapy exposures; only 3% (n=2/60) of patients discontinued therapy due to treatment-related adverse events • Breadth of res |
|
| March 17, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Kinnate Biopharma Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 |
|
| March 17, 2023 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 KINNATE BIOPHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 82-4566526 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 103 Montgomery Street, Suite 150 The Presid |
|
| March 15, 2023 |
KINNATE BIOPHARMA, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Exhibit 10.14 KINNATE BIOPHARMA, INC. AMENDED AND RESTATED OUTSIDE DIRECTOR COMPENSATION POLICY Kinnate Biopharma Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39743 KINNATE BIOPHA |
|
| March 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 15, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 15, 2023 |
Exhibit 99.1 Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates • Announced Phase 1 monotherapy dose escalation data for investigational pan-RAF inhibitor exarafenib (KIN-2787) was selected for an oral presentation at the American Association for Cancer Research 2023 Annual Meeting • Announced the company has initiated enrollment of patients into the mono |
|
| February 23, 2023 |
KNTE / Kinnate Biopharma Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 Kinnate Biopharma Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 49705R105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC OrbiMed Capital GP VIII LLC OrbiMed Asia GP IV, L.P. O |
|
| February 23, 2023 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated February 17, 2023, with respect to the common stock of Kinnate Biopharma Inc. |
|
| February 22, 2023 |
KNTE / Kinnate Biopharma Inc / Foresite Capital Fund IV, L.P. - SC 13D/A Activist Investment CUSIP NO. 49705R105 13D Page 1 of 16 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49705R105 (CUSIP Number) Dennis Ryan Foresite |
|
| February 21, 2023 |
Exhibit 99.1 Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China • Kinnate to retain Kinnjiu’s cash, intellectual property and other assets, including key personnel and legal entity structure • Kinnate’s cash runway |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 17, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
KNTE / Kinnate Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d37sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Kinnate Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 49705R105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statemen |
|
| February 14, 2023 |
KNTE / Kinnate Biopharma Inc / Nextech V Oncology S.C.S., SICAV-SIF - SC 13G/A Passive Investment SC 13G/A 1 tm236484d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock $0.0001 par value (Title of Class of Securities) 49705R 10 5 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 13, 2023 |
KNTE / Kinnate Biopharma Inc / Vida Ventures, LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KINNATE BIOPHARMA INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| January 26, 2023 |
Exhibit 99.1 Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director SAN FRANCISCO and SAN DIEGO, Calif. – January 26, 2023 – Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, J |
|
| January 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 25, 2023 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| January 23, 2023 |
SC 13G 1 p23-0318sc13g.htm KINNATE BIOPHARMA INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kinnate Biopharma Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSIP Number) January 13, 2023 (Date of Event Which Requires Filing of this Statement) Check th |
|
| November 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2022 Kinnate Biopharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNA |
|
| November 10, 2022 |
Exhibit 99.1 Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates ? Cash, cash equivalents and investments of $262.1 million as of September 30, 2022; cash runway expected to fund operations into mid-2024 SAN FRANCISCO and SAN DIEGO, Calif. ? November 10, 2022 ? Kinnate Biopharma Inc. (Nasdaq: KNTE) (?Kinnate?), a clinical-stage precision oncology comp |
|
| October 11, 2022 |
Exhibit 99.1 Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial ? KIN-2787 cleared the predicted efficacious dose at 300 mg bid; dose escalation continues with maximum tolerated dose not yet determined ? KIN-2787 achieved meaningful exposures that were dose proportional and exceeded the predicted effica |
|
| October 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 11, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| August 11, 2022 |
Exhibit 99.1 Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate Updates ? Phase 1 clinical trial for KIN-2787, the company?s investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate?s China joint venture ? U.S. Food and Drug Administration granted Orphan Drug Designation for KIN-2787 for the treatment of stage IIb-IV mel |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNATE BI |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission F |
|
| June 15, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 10, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| May 12, 2022 |
Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates Exhibit 99.1 Kinnate Biopharma Inc. Reports First Quarter 2022 Financial Results and Provides Operational Updates Initial monotherapy data from ongoing Phase 1 KN-8701 clinical trial expected in the fourth quarter of 2022 Announces initiation of the combination portion of Phase 1 KN-8701 clinical trial to evaluate its pan-RAF inhibitor, KIN-2787, with binimetinib in NRAS-mutant melanoma First pati |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNATE B |
|
| April 25, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy St |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39743 KINNATE BIOPHA |
|
| March 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 KINNATE BIOPHARMA INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forwar |
|
| March 28, 2022 |
Exhibit 4.3 DESCRIPTION OF SECURITIES General Kinnate Biopharma Inc. (?we,? ?our,? or ?us?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock, $0.0001 par value per share. The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and |
|
| March 28, 2022 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 KINNATE BIOPHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 82-4566526 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 103 Montgomery Street, Suite 150 The Pre |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 28, 2022 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Kinnate Biopharma Inc. (Exact name of registrant as specified in its charter) Table 1 ? Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.0001 |
|
| March 28, 2022 |
Exhibit 99.1 Kinnate Biopharma Inc. Reports Full Year 2021 Financial Results and Provides Operational Updates Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022 Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022 Initiation of the combination portion of KN-8701 to study KIN-2787 with binimetinib in NRAS-mutant melanoma expec |
|
| February 14, 2022 |
KNTE / Kinnate Biopharma Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Kinnate Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 49705R105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 10, 2022 |
KNTE / Kinnate Biopharma Inc / Vida Ventures, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* KINNATE BIOPHARMA INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| January 18, 2022 |
Exhibit 99.1 Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248 Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022 SAN FRANCISCO and SAN DIEGO, January 18, 2022 - Kinnate Biopharma Inc. (Nasdaq: KNTE) (?Kinnate?), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-tr |
|
| January 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 18, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| January 6, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission F |
|
| January 6, 2022 |
Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones Exhibit 99.1 Kinnate Biopharma Inc. Provides Corporate Update and Highlights Key Upcoming 2022 Milestones Announces proof-of-concept preclinical data demonstrating activity of KIN-2787 in NRAS-mutant melanoma Provides update on ongoing KN-8701 trial with expansion to include patients with NRAS-mutant melanoma in monotherapy and initiation of a combination portion with binimetinib planned for first |
|
| January 3, 2022 |
KINNATE BIOPHARMA INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT Exhibit 1.2 KINNATE BIOPHARMA INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT January 3, 2022 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Kinnate Biopharma Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with SVB Leerink LLC (the ?Agent?), as follows: 1. Issuance and Sale of |
|
| January 3, 2022 |
As filed with the Securities and Exchange Commission on January 3, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 3, 2022 Registration No. |
|
| January 3, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2022 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission F |
|
| January 3, 2022 |
KINNATE BIOPHARMA, INC. Dated as of , 20 TABLE OF CONTENTS Exhibit 4.6 KINNATE BIOPHARMA, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of |
|
| November 10, 2021 |
Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results Exhibit 99.1 Kinnate Biopharma Inc. Reports Third Quarter 2021 Financial Results In collaboration with Guardant Health, announced initial findings from BRAF Kinase Alteration Genomic Landscape and Real-World Clinical Outcomes Study Ended the quarter with cash, cash equivalents and investments of $347.9 million, exclusive of its China joint venture?s cash SAN FRANCISCO and SAN DIEGO, Calif. ? Novem |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNA |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2021 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| October 28, 2021 |
Exhibit 99.1 Kinnate Biopharma Inc. Announces Transition of Chief Scientific Officer Dr. Eric Murphy to serve on the company?s Scientific Advisory Board SAN FRANCISCO and SAN DIEGO, Calif. ? October 28, 2021 ? Kinnate Biopharma Inc. (Nasdaq: KNTE) (?Kinnate?), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 KINNATE BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39743 82-4566526 (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2021 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission F |
|
| August 16, 2021 |
Exhibit 99.1 Kinnate Biopharma Inc. Reports Second Quarter 2021 Financial Results Announced first patient dosed in Phase 1 trial evaluating KIN-2787 in patients with BRAF mutation-positive solid tumors Strengthened management team and Board of Directors with key appointments Ended the quarter with cash, cash equivalents and investments of $365.1 million, exclusive of $35.0 million in its China joi |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNATE BI |
|
| June 28, 2021 |
Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors Exhibit 99.1 Kinnate Biopharma Inc. Appoints Helen Sabzevari, Ph.D. to Board of Directors Accomplished immunologist and veteran biopharma executive has extensive experience in advancing pre-clinical stage oncology programs into the clinic SAN FRANCISCO and SAN DIEGO ? June 28, 2021 ? Kinnate Biopharma Inc. (Nasdaq: KNTE) (?Kinnate?), a biopharmaceutical company focused on the discovery and develop |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 KINNATE BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39743 82-4566526 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| June 15, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2021 KINNATE BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39743 82-4566526 (State or Other Jurisdiction (IRS Employer of Incorporation) |
|
| June 7, 2021 |
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT Exhibit 10.2 KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the ?Company?), and Neha Krishnamohan (?Executive?), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in connec |
|
| June 7, 2021 |
Exhibit 10.1 12707 High Bluff Drive, Suite 200 ? San Diego, CA 92130 O: 858.299.4699 April 15, 2021 Via Email Neha Krishnamohan [home address and email address redacted] Re: Employment Letter Dear Neha: On behalf of Kinnate Biopharma Inc. (the ?Company? or ?we?), I am pleased to offer you employment on the terms and conditions set forth in this employment letter agreement (the ?Agreement?), effect |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2021 KINNATE BIOPHARMA INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39743 82-4566526 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| June 7, 2021 |
Exhibit 99.1 Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team SAN FRANCISCO & SAN DIEGO, Calif. ? June 7, 2021 ? Kinnate Biopharma Inc. (Nas |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10‑Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10?Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39743 KINNATE B |
|
| May 17, 2021 |
Exhibit 99.1 Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787 KIN-2787 is the company?s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned initiation of Phase 1 clinical trial for KIN-2787 in mid-2021 Ended the quarter with cash and cash equivalents and investments of |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2021 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission File |
|
| May 13, 2021 |
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture Exhibit 99.1 Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture - Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite Capital - The joint venture will have exclusive license to develop and commercialize Kinnate?s currently most advanced kinase inhibitor candidates in Greater China - Veteran biopharm |
|
| May 13, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2021 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission File |
|
| April 30, 2021 |
DEF 14A 1 nc10022093x1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| April 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy St |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39743 KINNATE BIOPHA |
|
| March 29, 2021 |
Exhibit 99.1 Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers Progress towards IND filing for KIN-2787, our RAF inhibitor candidate, in the first half of 2021 and initiating a Phase 1 clinical trial later in the year remains on track Selected KIN-3248 as our lead FGFR inh |
|
| March 29, 2021 |
Exhibit 4.3 DESCRIPTION OF SECURITIES General Kinnate Biopharma Inc. (?we,? ?our,? or ?us?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our common stock, $0.0001 par value per share. The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and |
|
| March 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 brhc100223458k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 29, 2021 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Kinnate Biopharma Inc. (Name of Issuer) Common Stock $0.0001 par value (Title of Class of Securities) 49705R 10 5 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Kinnate Biopharma Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 49705R105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 16, 2021 |
CUSIP No. 49705R 10 5 13G Exhibit 99.1 JOINT FILING STATEMENT We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of Kinnate Biopharma Inc. is filed on behalf of each of us. Dated: February 16, 2021 Nextech V Oncology S.C.S., SICAV-SIF By: Nextech V GP S.à r.l. Its: General Partner By: /s/ Dalia Bleyer Dalia Bleyer, Managing Me |
|
| February 16, 2021 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KINNATE BIOPHARMA INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 49705R105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa |
|
| December 15, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No.)* Kinnate Biopharma Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 49705R105 (CUSIP Number) Dennis Ryan Foresite Capital Management, LLC 600 Montgomery |
|
| December 11, 2020 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated December 11, 2020, with respect to the ordinary shares of Kinnate Biopharma Inc. |
|
| December 11, 2020 |
PMVP / PMV Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Kinnate Biopharma Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 49705R105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) 739- |
|
| December 8, 2020 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. a Delaware corporation Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. a Delaware corporation Kinnate Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on January 4, 20 |
|
| December 8, 2020 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF KINNATE BIOPHARMA INC. (initially adopted on January 4, 2018) (as amended and restated on November 5, 2020 and effective as of the closing of the Company’s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL ME |
|
| December 8, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2020 Kinnate Biopharma Inc. (Exact name of registrant as specified in its charter) Delaware 001-39743 82-4566526 (State or other jurisdiction of incorporation) (Commission |
|
| December 8, 2020 |
Exhibit 99.1 Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares San Francisco and San Diego, Calif. December 7, 2020 – Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomicall |
|
| December 3, 2020 |
As filed with the Securities and Exchange Commission on December 3, 2020 Registration No. |
|
| December 3, 2020 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(4) Registration Nos. 333-250086 and 333-251089 12,000,000 Shares Common Stock This is the initial public offering of shares of common stock of Kinnate Biopharma Inc. We are offering 12,000,000 shares of common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price is $20.00 per share |
|
| December 2, 2020 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com December 2, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Celeste Murphy Julie Sherman Angela Connell Re: Kinnate Biopharma Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed |
|
| December 2, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 2, 2020 Registration No. |
|
| December 2, 2020 |
As filed with the Securities and Exchange Commission on December 2, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 KINNATE BIOPHARMA INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-4566526 11975 El Camino Real, Suite 101 San Diego, CA 92130 (858) 299-46 |
|
| November 30, 2020 |
November 30, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Celeste Murphy Julie Sherman Angela Connell Re: Kinnate Biopharma Inc. Registration Statement on Form S-1 File No. 333-250086 Acceleration Request Requested Date: December 2, 2020 Requested Time: 4:00 P.M. Easter |
|
| November 30, 2020 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com November 30, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Celeste Murphy Julie Sherman Angela Connell Re: Kinnate Biopharma Inc. Registration Statement on Form S-1 Filed November 13, 2020 |
|
| November 30, 2020 |
KINNATE BIOPHARMA INC. 2020 EQUITY INCENTIVE PLAN Exhibit 10.3 KINNATE BIOPHARMA INC. 2020 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Option |
|
| November 30, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 30, 2020 Registration No. |
|
| November 30, 2020 |
November 30, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 30, 2020 |
Exhibit 1.1 Kinnate Biopharma Inc. Common Stock, par value $0.0001 per share Underwriting Agreement [●], 2020 Goldman Sachs & Co. LLC SVB Leerink LLC Piper Sandler & Co. As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o SVB Leerink LLC 255 California Street, 12th Floor San Franci |
|
| November 30, 2020 |
KINNATE BIOPHARMA INC. 2020 EMPLOYEE STOCK PURCHASE PLAN Exhibit 10.4 KINNATE BIOPHARMA INC. 2020 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” under Code S |
|
| November 30, 2020 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. Kinnate Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Kinnate Biopharma Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delawar |
|
| November 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 KINNATE BIOPHARMA INC. (Exact name of registrant as specified in its charter) Delaware 82-4566526 (State of incorporation or organization) (I.R.S. Employer Identification No.) 11975 El Camino Real, |
|
| November 30, 2020 |
Exhibit 4.2 |
|
| November 30, 2020 |
AMENDMENT NUMBER THREE TO OFFICE LEASE Exhibit 10.16 AMENDMENT NUMBER THREE TO OFFICE LEASE This Amendment Number Three to Office Lease (“Third Amendment”), dated November 16, 2020 for reference purposes only, is made by and between REALTY INCOME PROPERTIES 14, LLC, a Delaware limited liability company (“Landlord”) and KINNATE BIOPHARMA INC., a Delaware corporation (“Tenant”) with reference to the following recitals. RECITALS A. Landlo |
|
| November 30, 2020 |
KINNATE BIOPHARMA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Exhibit 10.14 KINNATE BIOPHARMA, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Kinnate Biopharma Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (“Outside Directors”) |
|
| November 16, 2020 |
Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 o: 650. |
|
| November 13, 2020 |
Exhibit 4.1 KINNATE BIOPHARMA INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 24, 2020 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 3 2.1 Requested Registration 3 2.2 Company Registration 5 2.3 Registration on Form S-3 6 2.4 Expenses of Registration 7 2.5 Registration Procedures 8 2.6 Indemnification 9 2.7 Information by Holder |
|
| November 13, 2020 |
Exhibit 10.8 11975 El Camino Real, Suite 101 ♦ San Diego, CA 92130 O: 858.299.4699 ♦ F: 858.299.4204 November 9, 2020 Richard Williams c/o Kinnate Biopharma Inc. 11975 El Camino Real Suite 101 San Diego, CA 92130 Re: Confirmatory Employment Letter Dear Richard: This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Kinnate Biopharma Inc. (the “Company” or “ |
|
| November 13, 2020 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com November 13, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Celeste Murphy Julie Sherman Angela Connell Re: Kinnate Biopharma Inc. Amendment No. 2 to Draft Registration Statement on Form S- |
|
| November 13, 2020 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF KINNATE BIOPHARMA INC. (initially adopted on January 4, 2018) (as amended and restated on , 2020 and effective as of the closing of the Company’s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2. |
|
| November 13, 2020 |
AKINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT Exhibit 10.13 AKINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Richard Williams (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in conne |
|
| November 13, 2020 |
Exhibit 10.5 11975 El Camino Real, Suite 101 ♦ San Diego, CA 92130 O: 858.299.4699 ♦ F: 858.299.4204 November 9, 2020 Nima Farzan c/o Kinnate Biopharma Inc. 11975 El Camino Real Suite 101 San Diego, CA 92130 Re: Confirmatory Employment Letter Dear Nima: This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Kinnate Biopharma Inc. (the “Company” or “we”), ef |
|
| November 13, 2020 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. Kinnate Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: 1. The name of the Corporation is Kinnate Biopharma Inc. The Corporation’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delawar |
|
| November 13, 2020 |
Exhibit 10.6 11975 El Camino Real, Suite 101 ♦ San Diego, CA 92130 O: 858.299.4699 ♦ F: 858.299.4204 November 9, 2020 Mark Meltz c/o Kinnate Biopharma Inc. 11975 El Camino Real Suite 101 San Diego, CA 92130 Re: Confirmatory Employment Letter Dear Mark: This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Kinnate Biopharma Inc. (the “Company” or “we”), eff |
|
| November 13, 2020 |
Exhibit 10.15 OFFICE LEASE REALTY INCOME PROPERTIES 14, LLC, a Delaware limited liability company, as Landlord, and FOUNT THERAPEUTICS, LLC, a Delaware limited liability company, as Tenant. TABLE OF CONTENTS Page ARTICLE 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 2 ARTICLE 2 LEASE TERM 4 ARTICLE 3 BASE RENT 6 ARTICLE 4 ADDITIONAL RENT 6 ARTICLE 5 USE OF PREMISES 11 ARTICLE 6 SERVICES AND UTIL |
|
| November 13, 2020 |
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT Exhibit 10.10 KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Nima Farzan (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in connection |
|
| November 13, 2020 |
Exhibit 10.1 KINNATE BIOPHARMA INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Individuals are reluctant to serve as direct |
|
| November 13, 2020 |
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT Exhibit 10.11 KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Mark Meltz (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in connection w |
|
| November 13, 2020 |
Exhibit 10.2 KINNATE BIOPHARMA INC. 2018 EQUITY INCENTIVE PLAN (amended June 21, 2018; amended December 11, 2019 for share increase; amended May 27, 2020; amended July 17, 2020; amended August 22, 2020 for share increase) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional |
|
| November 13, 2020 |
Exhibit 10.7 11975 El Camino Real, Suite 101 ♦ San Diego, CA 92130 O: 858.299.4699 ♦ F: 858.299.4204 November 9, 2020 Eric Murphy c/o Kinnate Biopharma Inc. 11975 El Camino Real Suite 101 San Diego, CA 92130 Re: Confirmatory Employment Letter Dear Eric: This confirmatory employment letter agreement (the “Agreement”) is entered into between you and Kinnate Biopharma Inc. (the “Company” or “we”), ef |
|
| November 13, 2020 |
KINNATE BIOPHARMA INC. EXECUTIVE INCENTIVE COMPENSATION PLAN Exhibit 10.9 KINNATE BIOPHARMA INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payable to |
|
| November 13, 2020 |
BYLAWS OF KINNATE BIOPHARMA INC. Adopted January 4, 2018 TABLE OF CONTENTS Exhibit 3.3 BYLAWS OF KINNATE BIOPHARMA INC. Adopted January 4, 2018 TABLE OF CONTENTS Page ARTICLE I — MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders’ Meetings 2 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 3 1.9 Stockholder Action by Written Consent Without a Meeting 3 1.10 Record Dates |
|
| November 13, 2020 |
KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT Exhibit 10.12 KINNATE BIOPHARMA INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between Kinnate Biopharma Inc., a Delaware corporation (the “Company”), and Eric Murphy (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in connection |
|
| November 13, 2020 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 13, 2020 Registration No. |
|
| November 13, 2020 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. a Delaware corporation Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. a Delaware corporation Kinnate Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on January 4, 20 |
|
| November 3, 2020 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com November 3, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Celeste Murphy Julie Sherman Angela Connell Re: Kinnate Biopharma Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 |
|
| November 3, 2020 |
TABLE OF CONTENTS ? Amendment No. 2 to Draft Registration Statement, as confidentially submitted to the Securities and Exchange Commission on November 3, 2020 This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333-??????? UNITED STATES SECURITIES AND EXCHANGE COMMISSIO |
|
| October 16, 2020 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com October 16, 2020 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Celeste Murphy Julie Sherman Angela Connell Re: Kinnate Biopharma Inc. Draft Registration Statement on Form S-1 Submitted Septembe |
|
| October 16, 2020 |
Exhibit 10.12 OFFICE LEASE REALTY INCOME PROPERTIES 14, LLC, a Delaware limited liability company, as Landlord, and FOUNT THERAPEUTICS, LLC, a Delaware limited liability company, as Tenant. TABLE OF CONTENTS Page ARTICLE 1 PREMISES, BUILDING, PROJECT, AND COMMON AREAS 2 ARTICLE 2 LEASE TERM 4 ARTICLE 3 BASE RENT 6 ARTICLE 4 ADDITIONAL RENT 6 ARTICLE 5 USE OF PREMISES 11 ARTICLE 6 SERVICES AND UTIL |
|
| October 16, 2020 |
TABLE OF CONTENTS ? Amendment No. 1 to Draft Registration Statement, as confidentially submitted to the Securities and Exchange Commission on October 16, 2020 This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333-??????? UNITED STATES SECURITIES AND EXCHANGE COMMISSIO |
|
| September 4, 2020 |
TABLE OF CONTENTS ? As confidentially submitted to the Securities and Exchange Commission on September 4, 2020 This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. |
|
| September 4, 2020 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KINNATE BIOPHARMA INC. Kinnate Biopharma Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is Kinnate Biopharma Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State of Delawar |
|
| September 4, 2020 |
Exhibit 4.1 KINNATE BIOPHARMA INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT August 24, 2020 TABLE OF CONTENTS Page Section 1 Definitions 1 1.1 Certain Definitions 1 Section 2 Registration Rights 3 2.1 Requested Registration 3 2.2 Company Registration 5 2.3 Registration on Form S-3 6 2.4 Expenses of Registration 7 2.5 Registration Procedures 8 2.6 Indemnification 9 2.7 Information by Holder |
|
| September 4, 2020 |
BYLAWS OF KINNATE BIOPHARMA INC. Adopted January 4, 2018 TABLE OF CONTENTS Exhibit 3.3 BYLAWS OF KINNATE BIOPHARMA INC. Adopted January 4, 2018 TABLE OF CONTENTS Page ARTICLE I ? MEETINGS OF STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meeting 1 1.4 Notice of Stockholders? Meetings 2 1.5 Quorum 2 1.6 Adjourned Meeting; Notice 2 1.7 Conduct of Business 2 1.8 Voting 3 1.9 Stockholder Action by Written Consent Without a Meeting 3 1.10 Record Dates |
